Ticolubant
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Ticolubant is a chemical compound that has been studied for its potential use as a pharmaceutical agent. It is primarily known as a leukotriene B4 receptor antagonist, which means it can block the action of leukotriene B4 (LTB4), a molecule involved in inflammatory responses.
Pharmacology[edit | edit source]
Ticolubant functions by inhibiting the binding of leukotriene B4 to its receptor, BLT1. Leukotriene B4 is a potent chemoattractant involved in the recruitment of neutrophils and other immune cells to sites of inflammation. By blocking this pathway, ticolubant may reduce inflammation and the associated symptoms in various conditions.
Potential Therapeutic Uses[edit | edit source]
Ticolubant has been investigated for its potential in treating inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and other conditions characterized by excessive leukotriene activity. However, as of the latest updates, it has not been approved for clinical use.
Research and Development[edit | edit source]
Research on ticolubant has primarily focused on its pharmacokinetics, safety profile, and efficacy in preclinical and early clinical trials. Studies have shown that it can effectively reduce leukotriene B4-mediated responses in animal models, but further research is needed to establish its safety and efficacy in humans.
Mechanism of Action[edit | edit source]
Ticolubant acts as a competitive antagonist at the leukotriene B4 receptor, BLT1. By preventing LTB4 from binding to its receptor, ticolubant reduces the downstream signaling that leads to inflammation and immune cell recruitment.
Side Effects and Safety[edit | edit source]
The safety profile of ticolubant is still under investigation. Common side effects observed in early trials include headache, nausea, and dizziness. Long-term safety data are not yet available.
Regulatory Status[edit | edit source]
As of the latest information, ticolubant has not received approval from major regulatory agencies such as the FDA or EMA for clinical use. It remains an investigational compound.
Also see[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
